AiCuris has launched a four-pillar program, “PREP – Pandemic and Resistance Emergency Preparedness”
Royalty Pharma and AiCuris have entered into an agreement whereby Royalty Pharma has acquired a partial royalty interest on Prevymis™ (letermovir) from AiCuris for a one-time-payment of $220 million.
AiCuris has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for oral pritelivir, AiCuris’ lead candidate for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV)
“In times like these, biotech and pharmaceutical companies have a great societal responsibility”
AiCuris and myTomorrows today announced a collaboration to develop an Early Access Program (EAP) for pritelivir, currently undergoing Phase II testing for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
If you have a media enquiry or further questions regarding public relation activities at AiCuris please contact:
AiCuris Anti-infective Cures GmbH
Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1177